Evaluate the Evolution of Body and Scalp Skin Discomfort in Patients With Hereditary Ichthyosis After Wraps (EnvelopIchtyose)

NCT ID: NCT05979506

Last Updated: 2023-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-31

Study Completion Date

2025-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ichthyosis is a group of rare and chronic genetic diseases beginning at birth, in which the patient's skin is covered with scales of variable appearance and severity. This disease is disabling. The treatment is symptomatic and is based on the daily application of moisturizing creams with a high lipid content. Nevertheless, the effectiveness of these treatments is limited and are considered very painful by the patients. Wraps are local treatments carried out by specialized nurses and which consist in, following a therapeutic bath, applying a large quantity of cream to the whole body, followed by an occlusion. This type of care is simple to perform, but requires nursing expertise, to date, it is not carried out in standard practice in France, which is why the investigateur wish to evaluate the effect of wraps on different parameters reflecting the skin condition in the short and medium term.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ichthyosis is a group of rare and chronic genetic diseases beginning at birth, in which the patient's skin is covered with scales of variable appearance and severity. There are 2 distinct typical profiles: patients with thick scales without erythroderma and patients with finer scales on an erythrodermic background. This disease is disabling, in particular due to sensations of pruritus, skin pain and the possible presence of associated extra-cutaneous abnormalities. The treatment is symptomatic and is based on the daily application of moisturizing creams with a high lipid content for better effectiveness, keratolytic creams, and for severe forms, oral retinoids may be necessary. The creams improve the condition of the skin and reduce the sensations of skin discomfort, pain and pruritus, nevertheless, the effectiveness of these treatments is limited and are considered very painful by the patients.

Wraps are local treatments carried out by specialized nurses and which consist in, following a therapeutic bath, applying a large quantity of cream to the whole body, followed by an occlusion. The type of cream is adapted to the area of application: thus, an emollient cream is used for the body; a cream enriched with keratolytic active ingredients is used for the feet in the event of hyperkeratosis, and an emollient cream possibly enriched with keratolytic active ingredients is used for the scalp, followed by an exposure time under a steam helmet to remove scales. This type of care is simple to perform, but requires nursing expertise, to date, it is not carried out in standard practice in France, except in the centers of Toulouse, Bordeaux and Necker and at the thermal cure of Avène-les-Bains. However, the interest of such a treatment has never been evaluated independently, which is why in this study the investigators want to evaluate the effect of carrying out a daily treatment over 3 consecutive days, on different parameters reflecting the skin condition in the short and medium term

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ichthyosis Inherited

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Interventional, prospective, multicenter (Toulouse - Bordeaux - Paris Necker), comparative (baseline vs. short and medium term)
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Wraps (body and feet) as well as scalp care

The skin care consisting of wraps (body and feet) and scalp care, will be carried out consecutively over 3 days, in the hospital (outpatient or in day/traditional hospitalization).

Group Type EXPERIMENTAL

Cutaneous wraps

Intervention Type PROCEDURE

The topical treatment that will be used in this study are:

* For the body, an emollient cream with a high lipid content: Cold cream
* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage

Each of the 3 treatments (body, scalp and feet) will be carried out as follows:

* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes
* Occlusion by "wrapping" the patient in a plastic film, then covering with a blanket
* After 1 hour, the unabsorbed excess cream is removed with a towel

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cutaneous wraps

The topical treatment that will be used in this study are:

* For the body, an emollient cream with a high lipid content: Cold cream
* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage

Each of the 3 treatments (body, scalp and feet) will be carried out as follows:

* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes
* Occlusion by "wrapping" the patient in a plastic film, then covering with a blanket
* After 1 hour, the unabsorbed excess cream is removed with a towel

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with hereditary ichthyosis regardless of the clinical form
* Patient with a scaling or erythema score \> 6/16
* Patient with a skin discomfort score \> 3/10
* Patient having given written, free and informed consent
* Patient affiliated to a social security scheme

Exclusion Criteria

* Patient with a skin disease other than ichthyosis
* Patient having modified his treatments for ichthyosis in the month preceding inclusion
* Patient with known intolerance or allergy to one of the topicals used in the study
* Patient unable to complete the study questionnaires
* Patient under a protection regime
Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Toulouse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anne-Marie TRANIER

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toulouse University hospital

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anne-Marie TRANIER

Role: CONTACT

05 67 77 14 57

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anne-Marie TRANIER

Role: primary

0567771457

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC31/21/0341

Identifier Type: -

Identifier Source: org_study_id